NCI's PLCO study on ovarian cancer screening fails to improve mortality rates and confirms risks of false-positive surgical complications.
Limitations of Large-Scale Screening for Asymptomatic Women
The PLCO clinical trial (NCT01696994), led by the U.S. National Cancer Institute (NCI), evaluated the effectiveness of ovarian cancer screening in 78,216 asymptomatic women aged 55-74. This large-scale, randomized controlled study involved long-term follow-up for over 10 years, using a combination of annual Tumor Marker CA-125 blood tests and Transvaginal Ultrasound (TVU). Unfortunately, the study did not demonstrate a reduction in ovarian cancer mortality in the group that received regular screening compared to the control group receiving usual care. This is considered a clear example of the medical limitations where early detection does not necessarily lead to a decrease in mortality.
Risks of Overtreatment Due to False-Positive Diagnoses
The most significant finding of this study is that the physical harm caused by false-positive results outweighed the benefits. Among the women who underwent screening, 3,285 received false-positive results, and a significant 1,080 of these underwent unnecessary invasive ovarian surgery. Furthermore, 163 of the women who underwent surgery, representing 15%, experienced serious surgical complications such as infection and bleeding. This clearly warns of the risks of overdiagnosis and adverse effects that can arise from diagnostic protocols targeting the general asymptomatic population.
Paradigm Shift in the Global Cancer Diagnostics Market
The results of this study have completely changed the landscape of the global ovarian cancer diagnostics market. Based on this data, the U.S. Preventive Services Task Force (USPSTF) assigned a 'Grade D' recommendation, the strongest opposition, to ovarian cancer screening for the general female population. As a result, the growth of the multi-billion dollar mass screening market has been halted, and diagnostic companies have had to shift their focus from simple screening to high-risk group management or precision diagnostics. The global ovarian cancer diagnostics market is currently estimated at $1.6 billion to $4.9 billion, and is experiencing cautious growth under these regulatory guidelines.
Paradigm Shift to Next-Generation Liquid Biopsy Technologies
With the limitations of the existing CA-125 and ultrasound combination becoming clear, the industry is focusing on next-generation liquid biopsy technologies such as Multi-Cancer Early Detection (MCED). Grail's Galleri test and Exact Sciences' methylation DNA analysis are representative examples of these next-generation pipelines. In clinical practice, efforts are still being made to develop highly precise biomarkers that can improve the early detection rate of ovarian cancer while drastically reducing the false-positive rate. Ultimately, the failure of the PLCO study has formalized the departure of existing first-generation screening technologies and has served as a catalyst for accelerating disruptive innovation in the field of molecular diagnostics.
The PLCO clinical trial results served as a decisive turning point in the $1.6 billion to $4.9 billion global ovarian cancer diagnostics market, completely shrinking the business of general population screening based on existing CA-125 and transvaginal ultrasound. The USPSTF's Grade D recommendation and the failure to improve mortality rates (mortality ratio of 1.21) forced diagnostic device and analytical service development companies to reposition themselves towards high-risk group-targeted diagnostics or companion diagnostics, rather than targeting the general population. Researchers are focusing on comparative clinical trials with multi-cancer early detection (MCED) liquid biopsy platforms such as Grail's Galleri and the development of precision diagnostics pipelines to reduce the 15% rate of false-positive surgical complications. In the medium to long term, only precision diagnostics technologies based on unique biomarkers will be able to overcome market entry barriers, so investors should re-evaluate valuations based on clinical phase 3 data for new diagnostic platforms that innovatively reduce false positives.
Source: ClinicalTrials.gov (api_ct)